|

Pemetrexed (Alimta) Clinical Trials

4 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Alimta

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Intergroupe Francophone de Cancerologie Thoracique2
  • Gustave Roussy, Cancer Campus, Grand Paris1
  • Guangzhou Medical University1

Indications

  • Cancer4
  • Lung Cancer3
  • Intrathecal Drug Delivery1
  • MET Exon 14 Mutation1
  • Advanced Non-Small Cell Lung Cancer1

Other4 trials

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.